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Abstract
Introduction: Diagnosis of hepatocellular carcinoma (HCC) is considerably delayed, being frequently done in the non-curative 
stage of disease. The reason for delayed diagnosis is indolent course in early stages and/or unspecific symptoms indistinguish-
able from underlying cirrhosis. Hitherto methods used for screening of HCC have important limitations. TRIMprob is a non-inva-
sive method, which showed utility in detection of cancers located in prostate, breast, or urinary bladder. 
Aim: To determine the diagnostic accuracy of TRIMprob in detecting HCC in cirrhotic liver.
Material and methods: Forty-five patients were prospectively enrolled according to final clinical diagnosis into a group of 
cirrhosis and HCC or a group of cirrhosis without HCC. A control group consisted of 33 healthy subjects. Hepatocellular carcinoma 
was diagnosed by computed tomography (CT) or magnetic resonance (MR) and guided biopsy. The TRIMprob examination was 
performed in each patient. Three wave frequencies were used: 465, 930, and 1395 MHz.
Results: In patients with HCC the intensity of return signal using wave a frequency of 465 MHz was significantly reduced in 
patients with HCC in comparison to healthy subjects (p < 0.0005), but not to cirrhotic patients without HCC. Moreover, cirrhosis 
was associated with significantly decreased TRIMprob signal in comparison to healthy liver (p < 0.002). In ROC analysis an opti-
mal cut-off value for detection of HCC was 106 units, which yielded 80% sensitivity. 
Conclusions: TRIMprob identifies HCC with good sensitivity; however, the accuracy of this method to identify HCC in screen-
ing circumstances may be hindered by attenuation of the resonance interaction signal by cirrhosis itself. 
Introduction 
Hepatocellular carcinoma (HCC) is diagnosed yearly 
in more than 500,000 people worldwide [1]. It is the 
fifth most common cancer in men and the seventh in 
women, and it among the most aggressive of human tu-
mours [2]. In Europe the incidence of HCC ranges from 
2.9 to 5.2 cases per 100,000 [3]. Generally, this tumour 
shows a tendency towards increasing prevalence in de-
veloped countries, but its diagnosis is considerably de-
layed, being frequently done in the non-curative stage 
of disease. The reason for delayed diagnosis is indolent 
course in early stages and/or unspecific symptoms in-
distinguishable from underlying cirrhosis. The major risk 
factor for the development of HCC is liver cirrhosis of 
viral, alcoholic, or metabolic aetiology [2, 4]. The Euro-
pean Association for the Study of the Liver (EASL) and 
European Organisation for Research and Treatment of 
Cancer (EORTC) established criteria for diagnosis of HCC 
that incorporate both invasive and noninvasive mea-
sures [2]. Generally, the diagnosis of HCC is based on 
contrast imaging methods, and liver biopsy is reserved 
for diagnostically inconclusive cases.
Improving survival in HCC depends on access to 
sensitive, non-invasive, and cost-effective methods suit-
able for wide-ranged screening in high-risk populations. 
Tissue resonance interaction is a new method that 
analyses electromagnetic anisotropy in organic tissues. 
TRIMprob generates an alternating electromagnetic 
field that interacts with charged particles in a target tis-
sue, leading to a secondary radiation being a source re-
turn signal that varies for normal and neoplastic tissue 
[5]. Diagnosis of cancer by TRIMprob is mostly based 
on detection of the microtubules, which are cellular 
structures participating in mitotic division, more pre-
cisely in separation of chromatids [6]. The presence of 
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microtubules is characteristic for rapidly dividing cells. 
Using a wave frequency equal to half of the microtubule 
length was found to optimally detect cancerous growth. 
Several pilot clinical studies have shown that TRIMprob 
scanning is a valuable tool in diagnosing cancers de-
veloping in prostate [7–11], breast [12], stomach [13], 
thyroid gland [14], rectum [15], colon [16], or urinary 
bladder [17, 18]. 
Aim
The aim of this study was to determine the diagnos-
tic accuracy of TRIMprob in detecting HCC.
Material and methods
This study was conducted in a tertiary referral cen-
tre. Forty-five patients aged 22 to 85 years (56.3 ±15.0 
years) hospitalised in our department were prospective-
ly enrolled according to final clinical diagnosis either to 
the group of cirrhosis and HCC (n = 10) or to cirrhosis 
without HCC (n = 35). General demographic character-
istics of subjects are shown in Table I. The control group 
consisted of 33 healthy persons without history of liver 
or neoplastic disease, who did not show abnormalities 
at abdominal ultrasound and had normal transaminas-
es activity. 
The eligibility criteria for the study were: age > 18 
years (for all subjects) and presence of compensated or 
decompensated cirrhosis. The exclusion criteria were: 
body mass index (BMI) ≥ 40 kg/m², massive ascites, 
advanced encephalopathy, severe heart or lung fail-
ure, pacemaker implantation, the inability to maintain 
upright position, hepatic tumour other than HCC, and 
pregnancy.
The diagnosis of liver cirrhosis was based on a com-
bination of clinical, laboratory, radiological, endoscopic, 
and histopathological criteria. Arterial hypervascularity 
and venous/late phase washout were key criteria for 
diagnosis of HCC at multiphase computed tomography 
(CT) or dynamic contrast enhanced magnetic resonance 
(MR). Ultrasound-guided tumour biopsy was essential 
for the diagnosis of HCC in only 4 patients. 
Examination by TRIMprob was performed by a sin-
gle operator who, after short-term training, used in 
each patient the constant transabdominal “windows” 
specified in previous studies [13, 16]. During examina-
tion the patients were dressed in pyjamas or T-shirts, in 
an upright position, in front of the base of the device. 
The operator was standing on the right side of the pa-
tient with the probe in his right hand and touched the 
surface of the abdomen covered by clothing (Figure 1). 
The duration of examination was less than 5 min.
The probe emitted electromagnetic radiation of 
strength similar to that experienced during the use of 
a cordless telephone, of three frequencies: 465 MHz, 
930 MHz, and 1395 MHz. A spectrum analyser, fed by 
a receiving antenna, measured signal intensities that 
were graphically displayed on a computer screen, and 
the result was expressed in arbitrary units ranging be-
tween 0 and 255. 
The study conformed to the ethical guidelines of 
the 1975 Declaration of Helsinki (6th revision, 2008). All 
patients received detailed information about the pur-
Table I. Demographic and laboratory data of patients with liver cirrhosis with and without HCC
Variable Cirrhosis without HCC 
(n = 35)
Cirrhosis with HCC 
(n = 10)
P-value
Age, mean ± SD [years] 53.8 ±14.6 64.9 ±13.9 0.0757
Sex (male/female), n 20/15 5/5 0.9680
BMI, mean ± SD [kg/m2] 27.0 ±4.6 26.6 ±5.2 0.9424
Haemoglobin, mean [g/dl] 13.2 11.9 0.4798
Platelets, mean [× 103/mm3] 161 140 0.3324
Bilirubin, mean [mg/dl] 1.37 1.24 0.5480
Albumin, mean [g/dl] 2.90 3.80 0.5330
Alanine aminotransferase, mean [U/l] 42.5 40.0 0.8164
Aspartate aminotransferase, mean [U/l] 83.5 58.0 0.9022
INR, mean 1.16 1.23 0.5199
a-Fetoprotein, mean [ng/ml] 11.3 3.58 0.1201
In 33 control subjects (17 females) the mean age was 35.0 ±11.3 years, BMI was 29.3 ±3.2 kg/m2. INR – international normalised ratio.
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pose and character of the study and gave consent to 
participate.
Statistical analysis
Statistical analysis was conducted using Statistica 
version 12 software (StatSoft; Krakow, Poland). The dis-
tribution of quantitative variables was tested using the 
Shapiro-Wilk test and evaluated graphically by means 
of histograms. For variables having normal distribution, 
the means and standard deviations were calculated; for 
variables deviating from normal distribution, the me-
dian values were chosen. One-way ANOVA (one-way 
analysis of variance) or unpaired t test was applied to 
check the differences between the means of the stud-
ied groups. In the case of variables that did not meet 
the required assumptions, the Kruskal-Wallis one-way 
ANOVA or U Mann-Whitney test was used. ROC (Re-
ceiver Operating Characteristic) curves were used to 
evaluate the diagnostic test and determine the cut-off 
point. To define the relationships between the variables, 
analyses of correlations and regressions were conduct-
ed. The c2 test with Yates correction was used to eval-
uate the relationship between gender and belonging to 
a group. A p level less than 0.05 was considered statis-
tically significant.
Results
Alcoholic aetiology of cirrhosis was diagnosed in 11 pa- 
tients, chronic viral hepatitis B or C in 11 patients, 
autoimmune hepatitis in 12 patients, and metabolic 
(non-alcoholic steatohepatitis, Wilson disease, hered-
itary haemochromatosis) in 5 patients. No clear aeti-
ology of cirrhosis could be determined in 6 patients. 
Mild or moderate ascites was found in 10 patients. The 
mean diameter of HCC measured on ultrasound was 
42.6 ±13.2 mm. Mean value of a-fetoprotein (AFP) was 
803 ±2434 ng/ml in cirrhotic patients with HCC and 
7.6 ±9.1 ng/ml in those without HCC. 
The analysis of tissue resonance interaction by 
TRIMprob for frequency waves of 465 MHz, 930 MHz, 
and 1395 MHz is shown in Figure 2. For the frequen-
cy of 465 MHz the tissue resonance signals in patients 
with HCC, but also with cirrhosis without HCC, were 
significantly reduced in comparison to the individuals 
with healthy liver (p = 0.00025 and p = 0.0015, respec-
tively). Tissue resonance signals in cirrhotic patients 
with and without HCC were not statistically different 
for any wave frequency. For the frequency of 1395 MHz 
the TRIMprob signal was decreased in cirrhosis without 
HCC in relation to healthy liver (p = 0.00046). Signifi-
cant correlations were found between TRIMprob signal 
intensity (at 1395 MHz) and serum levels of bilirubin 
(r = –0.80007; p = 0.0054) and albumin (r = 0.79235; 
p = 0.0336) (Figure 3). There were no significant cor-
relations between signal intensity and such parameters 
as the tumour size, levels of transaminases, or platelet 
count. 
In ROC analysis an optimal cut-off value for dis-
crimination of HCC from healthy liver (at 465 MHz) was 
106 units, which yielded 80% sensitivity and 94% spec-
ificity (area under ROC curve was 0.865) (Figure 4). In 
this analysis the discrimination of cirrhosis with HCC 
from cirrhosis alone provided the same cut-off value 
and sensitivity but lower specificity (66%) with posi-
tive predictive value of 40% (area under ROC curve 
was 0.713). Table II summarises TRIMprob accuracy in 
discrimination between cirrhosis plus HCC and cirrho-
sis alone. When a two-step approach to diagnosis of 
HCC was tested, based on lower signal intensity than 
106 units (465 MHz, first step) and higher signal inten-
sity than 79 units (1395 MHz, second step), the diag-
nostic sensitivity was 90% and specificity was 77.1%.
Discussion
Surveillance of cirrhotic patients for detection of 
early HCC is realised by 6-month interval abdominal 
ultrasound and serum level of AFP. The diagnostic sen-
sitivity of ultrasound ranges from 58% to 89% [19–21]. 
Although the ultrasound is a readily available, non-in-
vasive, and relatively cheap method, the detection of 
early HCC in a fibrotic background may be challenging 
because the coarse pattern of hepatic echogenicity may 
deteriorate identification of small tumours. Because of 
these limitations, the performance of ultrasound in de-
tection of early HCC is dependent on the expertise of 
Figure 1. The position of the patient during  
TRIMprob examination
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the operator and the quality of the equipment [2]. AFP 
serum level exceeding 20 ng/ml shows average sensi-
tivity of 60% in diagnosis of HCC [22]. Setting a cut-off 
value at 200 ng/ml is associated with perfect specificity 
but a significant decline of the sensitivity to 22% [23]. 
Moreover, fluctuating serum levels of AFP in patients 
Figure 2. TRIMprob signal intensities registered 
in two groups of patients and healthy subjects 
at different frequency waves
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with cirrhosis may reflect bursts of viral replication or 
exacerbations of underlying liver disease [24]. For these 
reasons AFP is not recommended by EASL and EORTC 
for detection of early HCC [2]. Limitations of hitherto 
used methods to detect HCC arising in cirrhotic liver 
warrant the search for new non-invasive surveillance 
methods.
Vedruccio and Meessen put forward an idea of 
cancer detection based on non-linear resonance inter-
actions with microtubules, representative for rapidly 
growing cells [5]. The electromagnetic waves generat-
ed by the TRIMprob stimulate minute electrical oscil-
lations in biological tissues, which produce resonance 
effect of the magnitude dependent on the structural 
characteristics these tissues [7]. The receiver of the 
TRIMprob detects the signal originating from non-lin-
ear resonance interactions of intensity expressed in 
arbitrary units ranging between 0 and 255. TRIMprob 
is a simple, quick to perform (in this study examina-
tion took less than 5 min) test that does not require 
any prior preparation of the patient, yielding immedi-
ate and reproducible results [5, 6, 11]. Previous clinical 
studies have shown that TRIMprob scanning is useful in 
detecting cancers of different localisations. In a study 
by Bellorofonte et al. performed on 757 patients with 
prostate cancer TRIMprob showed good performance in 
detection of this neoplasm at a frequency of 465 MHz 
[7]. In other validating studies the diagnostic sensitiv-
ity of TRIMprob was 80% and 86% for prostate cancer 
[8, 9], 84% for breast cancer [12], 97.9% for urinary 
bladder cancer [18], 94% for rectal cancer [15], and 
98.7% for colon cancer [16]. In the majority of these 
studies 50 units was taken as the cut-off value optimal-
ly distinguishing cancerous from intact organ. 
To our knowledge, it is the first study to investigate 
TRIMprob for detection of HCC. In our study HCC was 
responsible for significant lowering of the TRIMprob sig-
nal in comparison with healthy liver. It is in accordance 
with other studies, in which cancers reduced the signal 
intensity recorded by TRIMprob. It should be noted that 
we tested TRIMprob for detection of advanced HCC be-
cause the mean diameter of the tumour was 4.2 cm. 
The performance of TRIMprob in detecting early HCC 
measuring 1–2 cm (target of ultrasound surveillance) 
with lower load of rapidly dividing cells remains un-
known.
In comparison to other cancers HCC shows sever-
al peculiarities, which may be important for TRIMprob 
measurements. First, the liver is a voluminous organ 
and HCC may be situated deep under the skin sur-
face. The influence of the distance from the probe to 
the tumour on signal intensity is not well known. In 
all published studies TRIMprob was used to search for 
cancers located in close proximity to the probe in such 
organs as breast, rectum, thyroid gland, or prostate. 
Second, in almost all cases HCC arises in cirrhotic liv-
er, while cancers in other organs develop in an intact 
background. This may be a reason for the considerably 
higher cut-off value discriminating cancer and non-can-
cer patients in relation to other studies (106 vs. about 
Figure 4. The ROC curves graph for accuracy of 
TRIMprob (465 MHz) to identify hepatocellular 
carcinoma (HCC)
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Table II. TRIMprob signal intensities according to the wave frequency and compared groups of subjects
Frequency 
wave 
[MHz]
Signal intensity in investigated 
groups [units]
mean ± SD (median)
Cut-off 
value 
[units]
Sensitivity 
(%)
Specificity 
(%)
PPV (%) NPV (%) AUROC P-value
Cirrhosis 
with HCC
Cirrhosis 
w/o HCC
Controls
465 67.0 ±67.2
(32.5)
113 ±59.6
(128)
162 ±32.6
(160)
106
106
80
80
94
66
80
40
94
92
0.865
0.713
< 0.0001a
< 0.05b
1395 98.3 ±35.6
(102)
57.6 ±47.7
(33)
102 ±42.5
(112)
120
79
90
90
45
63
33
41
94
96
0.571
0.731
0.4619a
< 0.005b
aComparison between cirrhosis with HCC and controls; bcomparison between cirrhosis with HCC and cirrhosis alone. PPV – positive predictive value,  
NPV – negative predictive value, AUROC – area under ROC curve, w/o – without.
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50 units). Until now, the influence of cirrhosis itself on 
TRIMprob recordings has been unclear. In our study the 
patients with cirrhosis and no evidence of HCC at im-
aging examinations showed decreased TRIMprob signal 
intensity, providing intermediate results between HCC 
and healthy liver. In physiological conditions the liver is 
an organ of low proliferative activity, but in cirrhosis cell 
proliferation may be enhanced as a sign of regeneration 
activity. Therefore, it may be speculated that decreased 
intensity of resonance signal is result of regenerative 
activity of cirrhotic liver and possibly its pre-neoplastic 
propensity. Interestingly, cirrhosis was associated with 
decreasing TRIMprob signal intensity with higher wave 
frequencies, and recordings at 1395 MHz correlated 
with albumin and bilirubin serum levels, the parameters 
reflecting liver function. These findings suggest that 
TRIMprob should be tested in the assessment of sever-
ity of liver fibrosis. 
Evidence that cirrhosis itself is responsible for reduc-
tion of TRIMprob decreases the diagnostic ability of this 
method to find HCC within cirrhotic liver. Nonetheless, 
TRIMprob showed satisfactory performance in detection 
of HCC in cirrhotic patients with 80% sensitivity. Low 
(66%) specificity could be entirely attributed to the ef-
fect of cirrhosis on resonance interaction. However, the 
specificity to detect HCC was significantly improved by 
accepting a two-step approach, using in the same pa-
tient with two different wave frequencies – 465 MHz 
and 1395 MHz. 
Conclusions
TRIMprob is a diagnostic technique that may iden-
tify HCC within cirrhotic liver; however, the accuracy of 
this method in screening circumstances may be hin-
dered by attenuation of the resonance signal by cirrho-
sis itself. 
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